These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 4775220)

  • 21. Fixed-duration multidrug therapy in multibacillary leprosy.
    Li HY; Hu LF; Wu PW; Luo JS; Liu XM
    Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):230-7. PubMed ID: 9251596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acid phosphatase activity of liver homogenates and its relation to drug activity in rats infected with Mycobacterium lepraemurium.
    Mathur IS; Gupta SK
    Int J Lepr Other Mycobact Dis; 1970; 38(3):264-70. PubMed ID: 5533689
    [No Abstract]   [Full Text] [Related]  

  • 23. Sulfanilamide in the treatment of leprosy. 1942.
    Faget GH; Johansen FA; Sister Hilary Ross
    Public Health Rep; 2006; 121 Suppl 1():221-3; discussion 220. PubMed ID: 16550782
    [No Abstract]   [Full Text] [Related]  

  • 24. Single-dose rifampicin, oflaxicin and minocycline (ROM) therapy for single leprosy lesions.
    Ramu G
    Lepr Rev; 1998 Mar; 69(1):78-82. PubMed ID: 9628098
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy of single-dose ROM therapy plus low-dose convit vaccine as an adjuvant for treatment of paucibacillary leprosy patients with a single skin lesion.
    Majumder V; Saha B; Hajra SK; Biswas SK; Saha K
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):283-90. PubMed ID: 11221091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rate of decline in bacterial index in leprosy; observations after three different chemotherapeutic interventions.
    Ganapati R; Pai VV; Shroff HJ; Gandewar K
    Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):264-6. PubMed ID: 9251604
    [No Abstract]   [Full Text] [Related]  

  • 27. Suppression of tumour necrosis factor-alpha expression in leprosy skin lesions during treatment for leprosy.
    Sugita Y; Miyamoto M; Koseki M; Ishii N; Nakajima H
    Br J Dermatol; 1997 Mar; 136(3):393-7. PubMed ID: 9115924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic prospects for paucibacillary leprosy.
    Katoch K
    Indian J Lepr; 2000; 72(3):351-61. PubMed ID: 11105276
    [No Abstract]   [Full Text] [Related]  

  • 29. Histological resolution and bacterial clearance with pulse ROM therapy in borderline lepromatous leprosy.
    Suneetha S; Reddy R
    Int J Lepr Other Mycobact Dis; 2001 Mar; 69(1):53-4. PubMed ID: 11480321
    [No Abstract]   [Full Text] [Related]  

  • 30. Leprosy and international adoption: a case report and review of diagnostic and treatment dilemmas.
    King K; Browning JC; Metry DW; Prestigiacomo J; Scollard D; Schutze GE; Stryjewska B; Schwarzwald H
    Pediatr Infect Dis J; 2009 Apr; 28(4):322-5. PubMed ID: 19238115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leprosy: diagnostic and control challenges for a worldwide disease.
    Goulart IM; Goulart LR
    Arch Dermatol Res; 2008 Jul; 300(6):269-90. PubMed ID: 18461340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct histopathological patterns in single lesion leprosy patients treated with single dose therapy (ROM) in the Brazilian Multicentric Study.
    Costa MB; Cavalcanti Neto PF; Martelli CM; Stefani MM; Maceira JP; Gomes MK; Schettini AP; Rebello PF; Pignataro PE; Ueda ES; Narahashi K; Scollard DM
    Int J Lepr Other Mycobact Dis; 2001 Sep; 69(3):177-86. PubMed ID: 11875761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single lesion paucibacillary leprosy: baseline profile of the Brazilian Multicenter Cohort Study.
    Martelli CM; Stefani MM; Gomes MK; Rebello PF; Peninni S; Narahashi K; Maroclo AL; Costa MB; Silva SA; Sacchetim SC; Nery JA; Salles AM; Gillis TP; Krahenbuhl JL; Andrade AL
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):247-57. PubMed ID: 11221086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Follicular mucinosis in suspected leprosy.
    Joshi RS
    Indian J Lepr; 2002; 74(4):341-7. PubMed ID: 12624983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve damage.
    Naafs B
    Int J Lepr Other Mycobact Dis; 1996 Dec; 64(4 Suppl):S21-8. PubMed ID: 9030120
    [No Abstract]   [Full Text] [Related]  

  • 36. Shortening duration of treatment of multibacillary leprosy. Action Programme for the Elimination of Leprosy, WHO.
    Indian J Lepr; 1997; 69(3):267-70. PubMed ID: 9394176
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of leprosy: science or politics?
    Naafs B
    Trop Med Int Health; 2006 Mar; 11(3):268-78. PubMed ID: 16553906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Epsilon-aminocaproic acid in the treatment of inflammatory manifestations in borderline leprosy. Apropos of 6 cases].
    Saint-André P; Ferracci C; Baquillon G; Ridel PR; Boucher P
    Acta Leprol; 1982; (86-87):199-208. PubMed ID: 6815989
    [No Abstract]   [Full Text] [Related]  

  • 39. [Advances in the chemotherapy of leprosy].
    Grosset J
    Med Trop (Mars); 1984; 44(1):17-22. PubMed ID: 6377002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Some new agents and methods in the treatment of leprosy].
    Loginov VK; Evstratova VA; Bragina VS; Sluvko ZA
    Vestn Dermatol Venerol; 1970 Jun; 44(6):37-40. PubMed ID: 5496831
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.